Market Overview:
Fanconi anemia (FA) is a rare, inherited blood disorder that affects about 1 in every 100,000 people. It occurs when the body can't properly repair damage to the bone marrow and other organs. This can lead to a shortage of red blood cells (anemia), white blood cells, and platelets. FA may also increase the risk of cancer. There is no cure for FA, but treatments are available to help manage its symptoms.
Product Definition:
Fanconi anemia (FA) is a rare, genetic disorder that affects the bone marrow and blood. People who have FA may not have enough red blood cells, white blood cells, or platelets. This can lead to anaemia (a lack of red blood cells), leukaemia (cancer of the white blood cells), and thrombocytopenia (a low number of platelets).
Fanconi anemia drug is important for people who have FA because it can help prevent or treat some of the problems caused by this disorder.
Eltrombopag Olamine:
Eltrombopag Olamine, also known as EMO-1 or Empagliflozin, is an investigational drug for Fanconi Anemia. It is a novel oral anticoagulant with low bioavailability developed by the pharmaceutical company named as Shire plc. The product was first presented at the American Society of Hematology in 2015 and has been under phase III clinical trial since then.
EXG-34217:
EXG-34217 is a selective inhibitor of the GIMME (exosome-associated) protein. It has been studied in combination with hydroxyurea and it's efficacy was compared to that of hydroxyurea alone in patients with Fanconi Anemia (FA). The study found that EXG-34217 increased the mean platelet volume by 37% and also improved bleeding time as well as reduced severe FA symptoms.
Application Insights:
The hospital application segment led the global fanconi anemia drug market in 2017. The high prevalence of chronic diseases, such as cancer and blood disorders, coupled with a rising number of transplant surgeries is expected to drive the hospital application segment over the forecast period.
Clinic applications for eltrombopag are rare due to its availability only through prescription from a healthcare professional. EXG-34217 is available OTC under specific conditions; however, it has not been approved by FDA for off-label use in patients with Fanconi syndrome or other indications where recombinant activated erythropoietin (rErypo) is used as a treatment option.
Other applications include research studies and gene therapy trials using exosomes or stem cells transfected with eltrombopag vector systemically administered via liposomal delivery systems or directly into cells via electroporation/carpel tunneling techniques.
Regional Analysis:
North America dominated the global fanconi anemia drug market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its large share. In addition, growing awareness about ESHF is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to unmet clinical needs and rising disposable income in emerging countries such as China and India. Moreover, government initiatives encouraging R&D activities are also expected to boost regional growth over the next eight years time frame. For instance, ‘One Health’ initiative by WHO has collaborated with governments across Asia Pacific region for disease control purposes including cancer research & development programs relatedto ESH Fanconi Anemia Drug Discovery Initiative (EDDI).
Growth Factors:
- Increasing incidence of Fanconi anemia
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective drugs for the treatment of Fanconi anemia
- Technological advancements in drug development process 5. Availability of government funding for research on Fanconi anemia
Scope Of The Report
Report Attributes
Report Details
Report Title
Fanconi Anemia Drug Market Research Report
By Type
Eltrombopag Olamine, EXG-34217, Fancalen, Others
By Application
Hospital, Clinic, Others
By Companies
Abeona Therapeutics Inc, Genethon SA, Novartis AG, Abeona Therapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Fanconi Anemia Drug Market Report Segments:
The global Fanconi Anemia Drug market is segmented on the basis of:
Types
Eltrombopag Olamine, EXG-34217, Fancalen, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abeona Therapeutics Inc
- Genethon SA
- Novartis AG
- Abeona Therapeutics Inc
Highlights of The Fanconi Anemia Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Eltrombopag Olamine
- EXG-34217
- Fancalen
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fanconi Anemia Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fanconi anemia drug is a medication used to treat Fanconi anemia. It helps to prevent the bone marrow from failing and allows the body to produce enough red blood cells.
Some of the major players in the fanconi anemia drug market are Abeona Therapeutics Inc, Genethon SA, Novartis AG, Abeona Therapeutics Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fanconi Anemia Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fanconi Anemia Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fanconi Anemia Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fanconi Anemia Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fanconi Anemia Drug Market Size & Forecast, 2020-2028
4.5.1 Fanconi Anemia Drug Market Size and Y-o-Y Growth
4.5.2 Fanconi Anemia Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Eltrombopag Olamine
5.2.2 EXG-34217
5.2.3 Fancalen
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fanconi Anemia Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fanconi Anemia Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Eltrombopag Olamine
9.6.2 EXG-34217
9.6.3 Fancalen
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Eltrombopag Olamine
10.6.2 EXG-34217
10.6.3 Fancalen
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Eltrombopag Olamine
11.6.2 EXG-34217
11.6.3 Fancalen
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Eltrombopag Olamine
12.6.2 EXG-34217
12.6.3 Fancalen
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Eltrombopag Olamine
13.6.2 EXG-34217
13.6.3 Fancalen
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fanconi Anemia Drug Market: Competitive Dashboard
14.2 Global Fanconi Anemia Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abeona Therapeutics Inc
14.3.2 Genethon SA
14.3.3 Novartis AG
14.3.4 Abeona Therapeutics Inc
